Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced
algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on …

Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies …

Sequencing has identified millions of somatic mutations in human cancers, but distinguishing
cancer driver genes remains a major challenge. Numerous methods have been developed …

The Cancer Genome Atlas (TCGA) has catalyzed systematic characterization of diverse
genomic alterations underlying human cancers. At this historic junction marking the completion …

Metastases are responsible for the majority of cancer-related deaths. Although genomic
heterogeneity within primary tumors is associated with relapse, heterogeneity among treatment-…

The functional impact of the vast majority of cancer somatic mutations remains unknown,
representing a critical knowledge gap for implementing precision oncology. Here, we report the …

MHC-I loss or downregulation in cancer cells is a major mechanism of resistance to T cell–based
immunotherapies. Our study reveals that birinapant may be used for patients with low …

Despite remarkable clinical efficacy of immune checkpoint blockade (ICB) in cancer treatment,
ICB benefits for triple-negative breast cancer (TNBC) remain limited. Through pooled in …

Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their
exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan-…

The impact of somatic missense mutation on cancer etiology and progression is often difficult
to interpret. One common approach for assessing the contribution of missense mutations in …